John F. Dipersio

Biography

  Dr. John F. DiPersio, M.D., Ph.D. serves as Chief of the Division of Oncology and Deputy Director of the Siteman Cancer Center. Dr. DiPersio is Vice President of American Society of Blood and Marrow Transplantation. He is Lewis T. and Rosalind B. Apple Professor of Medicine, Pediatrics and Pathology at Washington University School of Medicine. Dr. DiPersio is the Chief of the Division of Oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman Professor of Medicine. He runs a strongly successful Research Program that focuses on several aspects of T cell function, on Stem cell research and on Acute Myelogenous Leukemia, where he is recognized as a leading expert. He served as Vice President at American Society of Blood and Marrow Transplantation since 2016. He served as Guest Editor of Blood Journal since 1998. He served as a Member of External Advisory Panel, M.D. Anderson, (MDACC) PPG-AML since 1999 until 2006. He served as a Member of Career Development Award Study Section at Leukemia and Lymphoma Society of America since 2000 until 2006. He served as the Chairman of the Study Section RFA HL-04-017 (NHLBI) Specialized Center for Cell Based Therapy since 2005. He served as the Chairman of NIH/NIDDK P01 Special Emphasis Panel, Methylation and Hematopoiesis since 2011. He served as the Chairman of NIH NIAID ZAI1 MFH-01 P01 Special Emphasis Panel since 2010. He served as the Chairman of NHLBI Consensus Conference on Allo Transplantation for Non-Malignant Diseases since 2000. He served as Chief Resident at Parkland Memorial Hospital. He serves as a Member of Scientific Advisory Board at Amphivena Therapeutics, Inc. Dr. DiPersio has been a Member of Scientific & Industry Advisory Board at RiverVest Venture Partners, LLC since 2014. He serves as a Member of Clinical Advisory Board at Cellworks Group Inc. He serves as a Member of Advisory Board at Cellect Biotechnology Ltd. Dr. DiPersio serves as a Member of Oncology Advisory Board at Tioma Therapeutics, Inc. He serves as a Member of Scientific Advisory Board at Medros Inc. and Magenta Therapeutics, Inc. Dr. DiPersio is a member of the Board of Scientific Counselors (Clinical Science and Epidemiology) for the National Cancer Institute, an elected member of American Society for Clinical Investigation and American Academy of Physicians and the 2013 recipient of the Daniel P. Schuster Distinguished Translational Investigator Award. He is awarded as Alpha Omega Alpha at University of Rochester in 1980, Special Fellow - Leukemia Society of America in 1986, Junior Faculty Research Award at American Cancer Society in 1989, Bauman Award - Teacher of the Year, Internal Medicine, University of Rochester in 1992, Elected for American Society of Clinical Investigation (ASCI) in 1996, Recipient of Lewis T. and Rosalind B. Apple Chair in Oncology in 1997, ISHAGE Meeting, First prize, Scientific Merit: "Control of GvHD using genetically modified T cells" in 2001, "Great Teacher" Lecture NIH in 2008, Recipient of Virginia E. and Samuel J. Golman Endowed Professorship in Medicine in 2010, Washington University Divisions of Hematology and Oncology "Teacher of the Year" in 2010, Daniel P. Schuster Distinguished Translational Investigator Award, Washington University 2013, Member of Association of American Physicians (AAP) in 2013, Recipient of AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014, Thomson Reuters list of "Most Influential Scientific Minds" in 2014, American Society of Hematology Mentor Award for Clinical Investigation in 2014.Among his many accomplishments, he was instrumental in developing a drug called plerixafor that was approved by the U.S. Food and Drug Administration in 2008 to help treat multiple myeloma and non-Hodgkin's lymphoma. He served as a Member of Editorial Board - Journal of Experimental Hematology since 1993. He served as a Councilor of International Society of Experimental Hematology since 1997. He served as Member of Review Panel - Center Grants at National Medical Research Council, Singapore since 2009. He served as a Member of External Advisory Board at Cancer Therapy and Research Center - UT San Antonio since 2010. He served as a Member of Scientific and Medical Research Funding at California Institute for Regenerative Medicine (CIRM) since 2008 until 2011. He served at NIH (BST-M)/CSR- Special Emphasis Panel since 2011. He served at Study Section of Doris Duke Center Grants for Sickle Cell Disease since 2011. He served at NIH Study Section for Loan Repayment Program since 2012. He served as a Member of Barnard Free Skin and Cancer Board of Directors since 1998. He served as a Member of NCI Provocative Questions B Study Section since 2013. He served as a Member of Board of Scientific Councilors, National Cancer Institute (NCI) since 2013 until 2018. He served as Study Section Member at CPRIT (Cancer Prevention Research Institute of Texas) since 2014 until 2017. He served as Permanent Member at CIRM Working Group 2.0 since 2014. He served at American Cancer Society, National Board of Directors for Hope Lodges since 2015. He served as a Medical Advisory Board at Gabrielle's Angel Foundation for Cancer Research since 2015. He served as a Member of Board of Directors at American Society of Biology and Marrow Transplant since 2003 until 2006. He served at NIH (ZRG)/CSR – Gene Therapy and Inborn Errors – Special Emphasis Review Panel since 2006. He served as NCI (NIH) Permanent member and CONC Study Section Member since 2004 until 2009. Dr. Dipersio has provided invaluable expertise on the Molecular basis of Cancer and his advice is useful in focusing on optimizing the compounds for clinical trials as well as the trials themselves as Medros' lead compounds advance. His clinical research focuses on fundamental and translational aspects of leukemia and stem cell biology. He holds board certifications from American Board of Internal Medicine in 1984, American Board of Internal Medicine (Medical Oncology) in 1987 and American Board of Internal Medicine (Hematology) in 1988. Dr. DiPersio has authored or co-authored more than 275 publications and over 60 invited reviews and book chapters. He has been the Chief of Division of Oncology, Washington University School of Medicine, St. Louis, MO since 2000. He has been a Deputy Director of Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO since 2000. He has been a Professor of Medicine, Pediatrics and Pathology/Immunology, Washington University School of Medicine, St. Louis, MO since 1997. He served as an Instructor of Medicine - Division of Hematology-Oncology at UCLA School of Medicine, Los Angeles, CA from 1987 to 1988. He served as an Assistant Professor of Medicine, Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA from 1988 to 1990. He served as an Assistant Professor of Oncology at University of Rochester School o

Research Interest

Internal Medicine